Erratum to: Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus. Yanagihara TK, Tepper JE, Moon AM, et al. Pract Radiat Oncol. 2024 Mar-Apr;14(2):134-145

Ted K Yanagihara¹, Joel E Tepper², Andrew M Moon³, Aisling Barry⁴, Meritxell Molla⁵, Jinsil Seong⁶, Ferran Torres⁷, Smith Apisarnthanarax⁸, Michael Buckstein⁹, Higinia Cardenes¹⁰, Daniel T Chang¹¹, Mary Feng¹², Chandan Guha¹³, Christopher L Hallemeier¹⁴, Maria A Hawkins¹⁵, Morten Hoyer¹⁶, Hiromitsu Iwata¹⁷, Salma K Jabbour¹⁸, Lisa Kachnic¹⁹, Jordan Kharofa²⁰, Tae Hyun Kim²¹, Alexander Kirichenko²², Eugene J Koay²³, Hirokazu Makishima²⁴, Joel Mases²⁵, Jeffrey J Meyer²⁶, Pablo Munoz-Schuffenegger²⁷, Dawn Owen¹⁴, Hee Chul Park²⁸, Jordi Saez²⁵, Nina N Sanford²⁹, Marta Scorsetti³⁰, Grace L Smith²³, Jennifer Y Wo³¹, Sang Min Yoon³², Theodore S Lawrence³³, Maria Reig³⁴, Laura A Dawson³⁵

Affiliations

¹ Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. Electronic address: tky@unc.edu.
² Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
³ Ablative Radiotherapy Modified Delphi Steering Committee; Division of Gastroenterology and Hepatology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
⁴ Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Cork University Hospital, Cork, Ireland.
⁵ Ablative Radiotherapy Modified Delphi Steering Committee; Radiation Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain.
⁶ Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Yonsei University Medical College, Seoul, Republic of Korea.
⁷ Ablative Radiotherapy Modified Delphi Steering Committee; Biostatistics Unit, Medical School, Universitat Auntònoma de Barcelona, Barcelona, Spain.
⁸ Department of Radiation Oncology, University of Washington, Seattle, Washington.
⁹ Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
¹⁰ Department of Radiation Oncology, Weill Cornell Medicine, New York, New York.
¹¹ Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
¹² Department of Radiation Oncology, University of California, San Francisco, California.
¹³ Department of Radiation Oncology, Montefiore Hospital, New York, New York.
¹⁴ Department of Radiation Oncology, Mayo College of Medicine, Rochester, Minnesota.
¹⁵ Department of Radiation Oncology, University College London, London, England.
¹⁶ Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
¹⁷ Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya, Japan.
¹⁸ Department of Radiation Oncology, Robert Wood Johnson Medical School, Rutgers Cancer Institute, New Brunswick, New Jersey.
¹⁹ Department of Radiation Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.
²⁰ Department of Radiation Oncology, University of Cincinnati Cancer Center, Cincinnati, Ohio.
²¹ Department of Radiation Oncology, Proton Therapy Center, National Cancer Center, Seoul, Republic of Korea.
²² Department of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania.
²³ Department of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
²⁴ Department of Radiation Oncology, Proton Medical Research Center, University of Tsukuba, Tsukuba, Japan.
²⁵ Radiation Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain.
²⁶ Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
²⁷ Department of Hematology-Oncology, Pontificia Universidad Catolica de Chile, Santiago, Chile.
²⁸ Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
²⁹ Department of Radiation Oncology, University of Texas, Southwestern, Dallas, Texas.
³⁰ Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Milan, Italy.
³¹ Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
³² Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
³³ Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
³⁴ Ablative Radiotherapy Modified Delphi Steering Committee; Liver Cancer Unit. Liver Unit. Hospital Clínic, BCLC group - IDIBAPS, CIBEREHD, Barcelona University, Barcelona, Spain. Electronic address: mreig1@clinic.cat.
³⁵ Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Radiation Medicine Program/University Health Network, University of Toronto, Toronto, Canada.

PMID: 40155184
DOI: 10.1016/j.prro.2025.01.002

Published Erratum

Erratum to: Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus. Yanagihara TK, Tepper JE, Moon AM, et al. Pract Radiat Oncol. 2024 Mar-Apr;14(2):134-145

Ted K Yanagihara et al. Pract Radiat Oncol. 2025 Mar-Apr.

. 2025 Mar-Apr;15(2):214-215.

doi: 10.1016/j.prro.2025.01.002.

Authors

Affiliations

¹ Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. Electronic address: tky@unc.edu.
² Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
³ Ablative Radiotherapy Modified Delphi Steering Committee; Division of Gastroenterology and Hepatology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
⁴ Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Cork University Hospital, Cork, Ireland.
⁵ Ablative Radiotherapy Modified Delphi Steering Committee; Radiation Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain.
⁶ Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Yonsei University Medical College, Seoul, Republic of Korea.
⁷ Ablative Radiotherapy Modified Delphi Steering Committee; Biostatistics Unit, Medical School, Universitat Auntònoma de Barcelona, Barcelona, Spain.
⁸ Department of Radiation Oncology, University of Washington, Seattle, Washington.
⁹ Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
¹⁰ Department of Radiation Oncology, Weill Cornell Medicine, New York, New York.
¹¹ Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
¹² Department of Radiation Oncology, University of California, San Francisco, California.
¹³ Department of Radiation Oncology, Montefiore Hospital, New York, New York.
¹⁴ Department of Radiation Oncology, Mayo College of Medicine, Rochester, Minnesota.
¹⁵ Department of Radiation Oncology, University College London, London, England.
¹⁶ Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
¹⁷ Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya, Japan.
¹⁸ Department of Radiation Oncology, Robert Wood Johnson Medical School, Rutgers Cancer Institute, New Brunswick, New Jersey.
¹⁹ Department of Radiation Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.
²⁰ Department of Radiation Oncology, University of Cincinnati Cancer Center, Cincinnati, Ohio.
²¹ Department of Radiation Oncology, Proton Therapy Center, National Cancer Center, Seoul, Republic of Korea.
²² Department of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania.
²³ Department of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
²⁴ Department of Radiation Oncology, Proton Medical Research Center, University of Tsukuba, Tsukuba, Japan.
²⁵ Radiation Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain.
²⁶ Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
²⁷ Department of Hematology-Oncology, Pontificia Universidad Catolica de Chile, Santiago, Chile.
²⁸ Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
²⁹ Department of Radiation Oncology, University of Texas, Southwestern, Dallas, Texas.
³⁰ Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Milan, Italy.
³¹ Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
³² Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
³³ Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
³⁴ Ablative Radiotherapy Modified Delphi Steering Committee; Liver Cancer Unit. Liver Unit. Hospital Clínic, BCLC group - IDIBAPS, CIBEREHD, Barcelona University, Barcelona, Spain. Electronic address: mreig1@clinic.cat.
³⁵ Ablative Radiotherapy Modified Delphi Steering Committee; Department of Radiation Oncology, Radiation Medicine Program/University Health Network, University of Toronto, Toronto, Canada.

PMID: 40155184
DOI: 10.1016/j.prro.2025.01.002

No abstract available

PubMed Disclaimer

Erratum for

Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus.
Yanagihara TK, Tepper JE, Moon AM, Barry A, Molla M, Seong J, Torres F, Apisarnthanarax S, Buckstein M, Cardenes H, Chang DT, Feng M, Guha C, Hallemeier CL, Hawkins MA, Hoyer M, Iwata H, Jabbour SK, Kachnic L, Kharofa J, Kim TH, Kirichenko A, Koay EJ, Makishima H, Mases J, Meyer JJ, Munoz-Schuffenegger P, Owen D, Park HC, Saez J, Sanford NN, Scorsetti M, Smith GL, Wo JY, Yoon SM, Lawrence TS, Reig M, Dawson LA. Yanagihara TK, et al. Pract Radiat Oncol. 2024 Mar-Apr;14(2):134-145. doi: 10.1016/j.prro.2023.08.016. Epub 2024 Jan 19. Pract Radiat Oncol. 2024. PMID: 38244026

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Erratum to: Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus. Yanagihara TK, Tepper JE, Moon AM, et al. Pract Radiat Oncol. 2024 Mar-Apr;14(2):134-145

Affiliations

Erratum to: Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus. Yanagihara TK, Tepper JE, Moon AM, et al. Pract Radiat Oncol. 2024 Mar-Apr;14(2):134-145

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Miscellaneous